Protecting public health depends on the public trusting science, medicine and institutions. Demonstrating the effectiveness and safety of therapies and vaccines is an essential part of reinforcing that trust. ICON Government and Public Health has the knowledge, expertise and experience to support global clinical trials, analyse long-term patient data and provide real world solutions.
-
300+
Government sponsored clinical trials -
17,000+
Patients -
360
Dedicated government sites
Experience working with government
For more than 30 years, ICON has served as a trusted partner to multiple government agencies and federal contractors in both prime and subcontractor capacities. In addition, we support biotech, pharmaceutical, medical device and non-profit sponsors on government funded programs with comprehensive clinical and consulting services. Our federal clients include:
- Biomedical Advanced Research and Development Authority (BARDA)
- Defense Threat Reduction Agency (DTRA)
- Food and Drug Administration (FDA)
- Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEOCBRND)
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Disease (NIAID)
- United States Army Medical Research and Development Command (USAMRDC)
- Walter Reed Army Institute of Research (WRAIR)
ICON is a member of the following government consortiums:
- ARPA-H Customer Experience Hub
- Medical CBRN Defense Consortium (MCDC)
- Medical Technology Enterprise Consortium (MTEC)
- Rapid Response Partnership Vehicle (RRPV)
In partnership with BARDA, USAMRDC and WRAIR we seek new ways to protect and improve the health of veterans and serving members of the military.
Public Sector health
ICON Government and Public Health Solutions have extensive experience working with multi-national public health organisations and global NGOs, and are a qualified provider for the Gates Medical Research Institute. Our broad portfolio of services and global footprint also serve the needs of other global health organisations.
Public Health
Insights on disease prevention and control, health promotion and education, environmental health and health equity and social justice.
Incident Reporting Form
Transparency in coverage
This link leads to the machine readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine-readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.
In this section
-
Biotech
-
Early phase challenges for biotechs
-
Early phase development: Understanding key obstacles for biotechs in 2024
-
Emerging biotech funding
-
Externalised development for biotechs
-
Early engagement and regulatory considerations for biotech
-
De-risking clinical development of precision medicines in oncology
-
Methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
ICON survey report: CNS therapeutic development
-
Early phase challenges for biotechs
- Government and Public Health
- Medical Device
- Pharmaceuticals